Paris (France), 1 April 2015 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has signed a multi-year research alliance agreement with Harvard University in Cambridge, Mass.

Designed to stimulate new research projects, the alliance will enable researchers at Ipsen and Harvard to identify and develop collaborative programs in the areas of neuroendocrine tumors, neuromuscular disorders, and platform technologies related to toxins and peptides.

The agreement builds up on the success of an existing, three-year program initiated in July 2013: supported by Ipsen, the Harvard laboratory of Dr. Min Dong is engineering novel recombinant botulinum toxin molecules that may improve upon the therapeutic characteristics of existing treatments for neuromuscular tremors and spasms.

“This alliance represents Harvard’s continued commitment toward industry collaborations,” says Isaac T. Kohlberg, Harvard’s Chief Technology Development Officer and Senior Associate Provost. “We could not be more pleased to expand our productive relationship with Ipsen, advancing innovative research at Harvard, promoting scientific exchange, and partnering to make critical discoveries available for the benefit of society.”